Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies (Q40165130)

18 September 2017

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies (English)

1 reference

18 September 2017

chronic myeloid leukemia

0 references

1 reference

Jiang X

1

1 reference

18 September 2017

Zhao Y

2

1 reference

18 September 2017

Smith C

3

1 reference

18 September 2017

Gasparetto M

4

1 reference

18 September 2017

Turhan A

5

1 reference

18 September 2017

Eaves A

6

1 reference

18 September 2017

Eaves C

7

1 reference

18 September 2017

1 March 2007

1 reference

18 September 2017

1 reference

18 September 2017

21

1 reference

18 September 2017

926-935

1 reference

18 September 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404609

18 September 2017

0 references

cites work

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Fusion tyrosine kinases: a result and cause of genomic instability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Nonclonal hemopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Progress with chronic myelogenous leukemia: a personal perspective over four decades.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Growth autonomy and lineage switching in BCR-ABL-transduced human cord blood cells depend on different functional domains of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Fluorodeoxyuridine synchronization of hemopoietic colonies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404609

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404609

1 reference

Dimensions Publication ID

18 September 2017

0 references

1 reference